The estimated Net Worth of Danny L. Dearen is at least $19.1 Milión dollars as of 29 September 2023. Mr Dearen owns over 11,250 units of Axonics Inc stock worth over $2,161,696 and over the last 6 years he sold AXNX stock worth over $16,201,778. In addition, he makes $738,900 as Pres & CFO at Axonics Inc.
Mr has made over 28 trades of the Axonics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,250 units of AXNX stock worth $773,213 on 29 September 2023.
The largest trade he's ever made was selling 100,000 units of Axonics Inc stock on 20 April 2021 worth over $5,902,000. On average, Mr trades about 25,395 units every 47 days since 2019. As of 29 September 2023 he still owns at least 31,452 units of Axonics Inc stock.
You can see the complete history of Mr Dearen stock trades at the bottom of the page.
Danny L. Dearen is the Pres & CFO at Axonics Inc.
As the Pres & CFO of Axonics Inc, the total compensation of Mr Dearen at Axonics Inc is $738,900. There are 4 executives at Axonics Inc getting paid more, with Raymond Cohen having the highest compensation of $6,147,640.
Mr Dearen is 58, he's been the Pres & CFO of Axonics Inc since . There are 7 older and 13 younger executives at Axonics Inc. The oldest executive at Axonics Inc is Nancy Snyderman, 68, who is the Independent Director.
Danny's mailing address filed with the SEC is 26, Technology Drive, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik a Geoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
Axonics Inc executives and other stock owners filed with the SEC include: